Brokerages predict that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will announce earnings of $0.03 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at ($0.05). Amphastar Pharmaceuticals also posted earnings per share of $0.03 in the same quarter last year. The business is expected to announce its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.30 per share for the current financial year, with EPS estimates ranging from $0.19 to $0.45. For the next fiscal year, analysts anticipate that the company will post earnings of $0.95 per share, with EPS estimates ranging from $0.49 to $1.38. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. Amphastar Pharmaceuticals had a return on equity of 5.14% and a net margin of 0.74%. The company had revenue of $79.79 million during the quarter, compared to the consensus estimate of $76.21 million. During the same quarter in the prior year, the firm earned $0.05 EPS. The company’s quarterly revenue was up 36.7% compared to the same quarter last year.

AMPH has been the subject of a number of recent research reports. BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 10th. Needham & Company LLC downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective for the company. in a research report on Wednesday, March 13th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Piper Jaffray Companies downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $23.00 in a research report on Wednesday, March 13th. Finally, TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, March 18th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.05.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $21.97, for a total transaction of $219,700.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason B. Shandell sold 9,478 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $20.67, for a total transaction of $195,910.26. Following the sale, the general counsel now directly owns 159,947 shares in the company, valued at $3,306,104.49. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,078 shares of company stock worth $634,106. Company insiders own 30.80% of the company’s stock.

Large investors have recently made changes to their positions in the business. Nordea Investment Management AB raised its position in Amphastar Pharmaceuticals by 1.7% in the first quarter. Nordea Investment Management AB now owns 254,071 shares of the company’s stock worth $5,192,000 after purchasing an additional 4,343 shares in the last quarter. Sawtooth Solutions LLC acquired a new position in Amphastar Pharmaceuticals in the first quarter worth about $215,000. Federated Investors Inc. PA raised its position in Amphastar Pharmaceuticals by 8.7% in the first quarter. Federated Investors Inc. PA now owns 1,472,931 shares of the company’s stock worth $30,092,000 after purchasing an additional 117,480 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Amphastar Pharmaceuticals by 21.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 18,700 shares of the company’s stock worth $344,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Alambic Investment Management L.P. raised its position in Amphastar Pharmaceuticals by 364.4% in the first quarter. Alambic Investment Management L.P. now owns 68,564 shares of the company’s stock worth $1,401,000 after purchasing an additional 53,800 shares in the last quarter. 47.64% of the stock is currently owned by institutional investors.

Shares of NASDAQ:AMPH traded up $0.76 on Monday, reaching $20.58. 4,697 shares of the company traded hands, compared to its average volume of 202,200. Amphastar Pharmaceuticals has a fifty-two week low of $15.04 and a fifty-two week high of $25.43. The firm has a 50 day simple moving average of $21.05. The stock has a market cap of $932.84 million, a PE ratio of 97.95 and a beta of 1.39. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.06 and a quick ratio of 1.35.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: Commodities

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.